NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Hossam El Benawi: Loading Dose While Treating LVT Could Mitigate Stroke
Hossam El Benawi/LinkedIn
Oct 20, 2025, 05:18

Hossam El Benawi: Loading Dose While Treating LVT Could Mitigate Stroke

Hossam El Benawi, Senior Clinical Research Fellow of Cardiovascular Medicine at Mayo Clinic, shared on LinkedIn:

”’Loading Dose’ while treating Left ventricular thrombus could mitigate one of its most serious complication ”stroke”.

While many studies have compared DOACs and VKAs for the treatment of left ventricular thrombus (LVT), there is limited data on whether initiating treatment with a loading dose of DOACs can help prevent embolization.”

Mayo Clinic Multi-Center LVT study about DOAC Loading dose:

All over our study, 10 embolism events (DOAC: 4, VKA: 6).

· 50% of events (5/10) occurred within the first 8 weeks after LVT diagnosis.

Group comparison:

-At 6 months: DOAC 4.3% vs. VKA 1.8% (p = 0.37). Figure A

-All follow up: DOAC 5.7% vs. VKA 5.4% (p = 1.0). Figure B

In a subgroup analysis of patients treated with DOAC, we compared those with and without DOAC loading doses to the VKA group during the first 6 months.

-SSE ( systemic embolic events) incidence: 0% (loaded DOAC) vs. 5.7% (non-loaded DOAC) vs. 1.8% (VKA), p = 0.26. Figure C

-Events: 0/18 (loaded DOAC) vs. 3/52 (non-loaded DOAC) vs. 2/112 (VKA).

Numerically fewer SSE events in DOAC loading group vs. non-loading and VKA, but not statistically significant, likely due to small sample size).

Since 50% of embolization events occurred within the first 8 weeks, predominantly in the non-loading group, these findings suggest that initiating a loading phase early in treatment may be a more appropriate—and more consistent with FDA labeling for acute thrombosis—strategy to reduce SSE in patients with LVT.

Mayo Clinic Multi Center LVT Study, Part 1
Study Link”

Read the full article here.

Article: Comparison of Direct Oral Anticoagulants and Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi, A Retrospective Cohort Study

Authors: Hossam Elbenawi, Kirsten Lipps, Samuel Heller Jr., David A. Liedl, Raymond C. Shields, Ana I. Casanegra, Stanislav Henkin, Thom W. Rooke, Paul W. Wennberg, Waldemar E. Wysokinski, Robert D. McBane, Damon E. Houghton

Hossam El Benawi: Loading Dose While Treating LVT Could Mitigate Stroke

 

Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.

Ana I. Casanegra Damon E Houghton David A. Liedl DOACs FDA Health Hematology Hemostasis Hemostasis Today Hossam El Benawi Kirsten Lipps Left Ventricular Thrombus LVT Mayo Clinic Medicine Paul W. Wennberg Raymond C. Shields Robert D. McBane Samuel Heller Jr. Stanislav Henkin stroke Thom W. Rooke thrombosis VKAs Waldemar E. Wysokinski
NewsFeed